CClinicalTrials.gg
TerminatedNCT03440944Updated Apr 29, 2021Results posted

Superior Venous Access, Midline vs Ultrasound IVs

An interventional study of Ultrasound Guided Peripheral IV Catheter and Midline Catheter in Vascular Access Complication and Ultrasound Therapy; Complications, sponsored by Boston Medical Center. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-29.

Sponsored by Boston Medical Center · Not applicable, Interventional, and Treatment

Why this study was terminated
The study was stopped after a pause due to COVID-19 policies and new published evidence about the effectiveness of the interventon.
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Obtaining intravenous access (IVA) is the most common procedure performed in the emergency department (ED). Placement of IVA allows for blood work and delivery of intravenous fluids and medications. The implementation of ultrasound guided peripheral IVs (UGPIV) have allowed for ultrasound to be used to place an IV into patients with difficult vein access (DVA). An alternative device to place is a midline catheter (MC). The use of MCs against UGPIV has not been compared in a randomized study. Aim 1: To determine if UGPIVs have a higher failure rate than midline catheters within 72 hours of placement. Aim 2: To collect information to perform a direct cost analysis of UGPIV against that of the midline catheter. Aim 3: Assess patient satisfaction.

Read the detailed description

This is a randomized controlled trial to determine if the midline catheter is superior to the ultrasound guided IV with respect to survival at 72 hours.

Aim 1: To determine if UGPIVs have a higher failure rate than midline catheters within 72 hours of placement. There are several reasons why UGPIVs may fail. UGPIVs are shorter than midline catheters, and shorter catheters may fail due to infiltration which can be a result of malposition as well as having the catheter pull out of the vessel. It is being hypothesized that by using a midline catheter with a guidewire for placement with additional catheter length placed into the vessel, midlines will be superior to UGP\Vs with regards to survival time of the catheter. The investigators will assess catheter survival daily until 72 hours (when UGPIV are recommended to be changed). The total lifetime of the midline catheters will be recorded.

Aim 2: To perform a direct cost analysis of UGPIV against that of the midline catheter. This study will not be large enough to complete a robust cost effectiveness analysis to compare UGPIV to mid line catheters. As a part of this study the investigators will collect information including but not limited to: the number of catheters used for IVA attempts, time for placement of each device complications, and need for additional IVA during hospitalization.

Aim 3: For patients that remain hospitalized at 72 hours a satisfaction survey will be administered to determine patient experience and preference for the type of vascular access that they receive.

02

Conditions studied

  • Vascular Access Complication
  • Ultrasound Therapy; Complications

Keywords

  • vascular access
  • midline cather
  • ultrasound guided IV
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient at least 18 years of age being treated in the emergency department at Boston Medical Center
  • Standard IVA cannot be obtained by two qualified ER staff
  • Have an upper extremity (left or right arm) that can accept a deep venous IV
  • Clinical team believes the patient is likely to require inpatient admission at time of needing IV access
  • English speaking
  • Able to provide consent

Exclusion criteria

Exclusion Criteria:

  • Patient expected to be discharged from the emergency department or discharged from the hospital within 1 nights stay.
  • Prisoner
  • Pregnancy
  • Requires central line or midline catheter as an expected requirement of care
  • Patients who are expected to require medication that is not approved for administration via a peripherally guided IV or midline as defined by hospital pharmacy guidelines.
  • Patients known to have bacteremia or have a high suspicion of bacteremia
  • The patient is known or is suspected to be allergic to materials contained in the device
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Active comparator
    Ultrasound Guided Peripheral IV Catheter

    Patients if randomized to this group will receive a standard ultrasound guided peripheral IV. The IV is 4.88cm in length.

    Device: Ultrasound Guided Peripheral IV Catheter

  • Active comparator
    Midline Catheter

    Patients if randomized to this group will receive a midline catheter. The catheter is 10cm in length.

    Device: Midline Catheter

Interventions

  • DeviceUltrasound Guided Peripheral IV Catheter

    Patients randomized to this arm will receive an ultrasound guided peripheral IV catheter.

  • DeviceMidline Catheter

    Patients randomized to this group will receive a midline catheter. The catheter is 10cm in length.

05

What researchers measure

Primary outcomes

  1. Device Failures Within 72 Hours

    Total number and percentage of device failures within 72 hours of placement based on midline and ultrasound guided peripheral IV catheter. Medical record review and in person visits with medical treatment teams and patients were used to assess if device failure occurred within 72 hours. Device failure was determined by needing to have any device replaced or removed for clinical care.

    Time frame: 72 hours after device placement

Secondary outcomes

  1. IV Catheter Insertion Time

    The time it takes to insert the IV catheter will be documented in minutes for each study participant.

    Time frame: from catheter insertion

  2. Total Number of Replacement Catheters

    The total number of replacement IV catheters will be documented. This will be assessed based on each group (Ultrasound Guided Peripheral IV Catheter and Midline Catheter).

    Time frame: from catheter insertion up to 30 days

  3. Catheter Related Costs

    The mean costs per patient associated with the placement and replacement of catheters for each participant will be calculated.

    Time frame: from catheter insertion up to 30 days

  4. Patient Satisfaction

    Participant experience and satisfaction will be assessed with a short survey that will be given to participants who stay at least 72 hours after catheter insertion.

    Time frame: 72 hours after catheter insertion

06

Results

Posted Apr 29, 2021

Participant flow

Participant flow — Overall Study
MilestoneUltrasound Guided Peripheral IV CatheterMidline Catheter
Started99
Completed88
Not completed11
Withdrew: Physician decision10
Withdrew: No acceptable vasculature01

Outcome measures

PrimaryDevice Failures Within 72 Hours

Total number and percentage of device failures within 72 hours of placement based on midline and ultrasound guided peripheral IV catheter. Medical record review and in person visits with medical treatment teams and patients were used to assess if device failure occurred within 72 hours. Device failure was determined by needing to have any device replaced or removed for clinical care.

Time frame:
72 hours after device placement
Reported as:
Count of participants · Participants
Device Failures Within 72 Hours
ParticipantsUltrasound Guided Peripheral IV CatheterMidline Catheter
Device Failure within 72 hours61
No Device Failure within 72 hours27
SecondaryIV Catheter Insertion Time

The time it takes to insert the IV catheter will be documented in minutes for each study participant.

Time frame:
from catheter insertion
Reported as:
Median · minutes
IV Catheter Insertion Time
minutesUltrasound Guided Peripheral IV CatheterMidline Catheter
IV Catheter Insertion Time9 (7 to 13)17.5 (14 to 25)
SecondaryTotal Number of Replacement Catheters

The total number of replacement IV catheters will be documented. This will be assessed based on each group (Ultrasound Guided Peripheral IV Catheter and Midline Catheter).

Time frame:
from catheter insertion up to 30 days
Reported as:
Number · additional IV access devices
Total Number of Replacement Catheters
additional IV access devicesUltrasound Guided Peripheral IV CatheterMidline Catheter
Total Number of Replacement Catheters131
SecondaryCatheter Related Costs

The mean costs per patient associated with the placement and replacement of catheters for each participant will be calculated.

Time frame:
from catheter insertion up to 30 days
Reported as:
Mean · US Dollars
Catheter Related Costs
US DollarsUltrasound Guided Peripheral IV CatheterMidline Catheter
Catheter Related Costs38.25 ± 21.9528.88 ± 4.68
SecondaryPatient Satisfaction

Participant experience and satisfaction will be assessed with a short survey that will be given to participants who stay at least 72 hours after catheter insertion.

Time frame:
72 hours after catheter insertion
Reported as:
Count of participants · Participants
Patient Satisfaction
ParticipantsUltrasound Guided Peripheral IV CatheterMidline Catheter
Prefer Midline43
Unsure30
No10

Adverse events

Collected over Within 30 days of IV or Midline device placement. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ultrasound Guided Peripheral IV Catheter0/8 (0%)0/8 (0%)6/8 (75%)
Midline Catheter0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventUltrasound Guided Peripheral IV CatheterMidline Catheter
Device FailureSurgical and medical procedures6/81/8

Baseline characteristics

Only patients that received Ultrasound Guided Peripheral IV or Midline Catheter underwent analysis.

Age, Categorical
Age, Categorical(Participants)Ultrasound Guided Peripheral IV CatheterMidline CatheterTotal
<=18 years000
Between 18 and 65 years7714
>=65 years112
Age, Continuous
Age, Continuous(years)Ultrasound Guided Peripheral IV CatheterMidline CatheterTotal
Median42 (36 to 58)53 (43 to 62)49 (38 to 60)
Sex: Female, Male
Sex: Female, Male(Participants)Ultrasound Guided Peripheral IV CatheterMidline CatheterTotal
Female6713
Male213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ultrasound Guided Peripheral IV CatheterMidline CatheterTotal
Hispanic or Latino022
Not Hispanic or Latino8614
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ultrasound Guided Peripheral IV CatheterMidline CatheterTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American5510
White336
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Ultrasound Guided Peripheral IV CatheterMidline CatheterTotal
United States8816
07

Study locations

1 site
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Mar 29, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03440944
Lead sponsor
Boston Medical Center
Collaborators
Society for Academic Emergency Medicine, Bard Peripheral Vascular, Inc.
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
Apr 23, 2018
Primary completion
Jan 25, 2021
Completion
Jan 25, 2021
Results posted
Apr 29, 2021
Last update
Apr 29, 2021

Study contacts

Joseph Pare, MD MHS RDMS
principal investigator · Boston Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion